Respiratory Viral Articles & Analysis
19 news found
Funding from the BARDA Division of Research, Innovation, and Ventures (DRIVe) enabled the company to reformulate LMN-301, previously developed for oral delivery, and to evaluate its potential as an anti-viral therapeutic delivered to the respiratory tract, the primary site of SARS-CoV-2 infection. ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022 Advancing two additional virus-specific T cell ...
ByKalaris
Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio™ was effective in slowing the ...
Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio™ was effective in slowing the ...
The primary efficacy endpoint is the reduction in viral load at Week 4. About Respiratory Viral Infections and the ALVR106 Phase 1/2 Study Upper respiratory tract infections due to hMPV, influenza, PIV and RSV are detected in up to 40% of allo-HCT patients. In approximately half of these patients, these viral ...
ByKalaris
In a recent article, Prof Daniel Salerno, Prof Victor Kim and colleagues used Functional Respiratory Imaging to better understand the crucial link between DLCO and Pulmonary Vascular Abnormalities in COVID19. COVID-19 is a respiratory viral illness causing pneumonia and systemic disease. Abnormalities in pulmonary function tests infection have ...
ByFluidda
Data will be presented at American Society for Virology (ASV) 2021 and are available on bioRxiv REDWOOD CITY, Calif., July 19, 2021 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the ...
Paul Rota, Chief of the CDC’s Viral Vaccine Preventable Diseases Branch. Enrollment for the clinical trial is expected to continue through the second half of 2021, with results expected to be available in the first half of 2022. ...
· No vaccine is currently approved to protect against respiratory syncytial virus (RSV) · RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine · Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, appropriately ...
This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory conditions. ...
Initial preclinical data shows MV-014-212 induced a SARS-CoV-2-specific mucosal IgA response, generated serum neutralizing antibodies, and provided efficacy against challenge REDWOOD CITY, Calif., March 16, 2021 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, ...
The GC-IMS platform already has proven capability in differentiating between bacterial and viral respiratory infections as well as detecting a range of other infectious and inflammatory diseases and ...
- The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV) - Previous clinical data shows MV-012-968 is well-tolerated, heavily attenuated, and induces an RSV-specific mucosal IgA response in healthy seropositive adults and pediatric participants ...
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA ...
N8 Medical’s CeraShield™ Endotracheal Tube has a patented anti-fouling coating that is designed to prevent deadly bacterial infections that frequently occur in ventilated patients with respiratory viral infections. In contrast, conventional endotracheal tubes allow pathogenic bacteria to grow on the tube surfaces within hours and form slime-like ...
Cleaning of visibly dirty surfaces followed by disinfection is a best practice measure for prevention of COVID-19 and other viral respiratory illnesses in community settings. ONSLAUGHT, EPA registration number 61178-1-88903, from Bad Axe Restoration Products is the ideal solution for 1-step cleaning and disinfecting for SARS-CoV-2 and many other pathogens. ...
SOUTH SAN FRANCISCO, Calif, January 10, 2020 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MV-012-968, an investigational, live attenuated vaccine for protection against ...
The study will also explore whether traffic exposure has any effects on the likelihood of respiratory viral infections and will help researchers improve the predictive capabilities of computer models. ...